sulphonylurea


Also found in: Thesaurus, Medical, Wikipedia.

sulphonylurea

(ˌsʌlfənɪlˈjʊərɪə)
n
an antidiabetic drug used in treating type II diabetes, which acts by stimulating the production of insulin in the pancreas
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
References in periodicals archive ?
In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor, biguanide, sulphonylurea and GLP1 receptor agonist.
It was designed to assess the effect of Trajenta (linagliptin) (5 mg once daily) compared to the sulphonylurea glimepiride (both added to stable background glucose-lowering medication and cardiovascular standard of care) on cardiovascular safety in adults with type 2 diabetes and increased cardiovascular risk or established cardiovascular disease.
In PROFAS-IT study the dose of sulphonylurea was reduced by 50%, they were included in the study 2-4 week's pre-Ramadan.
daily; OHA: Oral hypoglycemic agents; P: Placebo; PIO: Ploglitazone; S: Sitagliptin; SGLT-2: Sodium-glucose co transporter type 2; SU: Sulphonylurea; W: weeks.
Following detection of the ABCC8 mutation, a trial of sulphonylurea (SU) treatment was commenced in the index case and his mother, who had been on insulin therapy for 13 years in an outpatient setting (Table 2).
A randomized controlled trial comparing the GLP 1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.
Another possible reason for the incomplete CNS response to sulphonylurea treatment in people with KCNJ11 PNDM is that therapeutic concentrations of sulphonylurea are not achieved in the human CSF.
In addition, 70% of the elderly diabetics were on sulphonylurea, especially glibenclamide when they had hypoglycaemia.
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
If used alongside a sulphonylurea (SU), the SU dose may need to be reduced in order to minimise the risk of hypoglycaemia.
All patients however should be assessed for surreptitious insulin or sulphonylurea use, the latter with a urinary sulphonylurea metabolite analysis.